lonafarnib has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 1 studies
Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) | Trials (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) | Recent Studies (post-2010) (2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one) |
---|---|---|---|---|---|
224 | 34 | 90 | 4,823 | 5 | 1,810 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
1 other study(ies) available for lonafarnib and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
Article | Year |
---|---|
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin | 2005 |